Background: Escherichia coli is part of the normal human intestinal microflora, although it has the potential of causing a variety of invasive and diarrheal diseases. It is also a frequent cause of community-and hospital-acquired urinary tract infections. Intestinal E. coli has the potential to rapidly develop multidrug resistant (MDR) and to emerge as extended-spectrum β-lactamases (ESBLs)-producer.
Introduction
The increased incidence of ESBLs, that make Gramnegative bacteria frequently resistant to penicillins, cephalosporins and aztreonam by hydrolyzing them, is becoming a global health problem [1] .
Class of CTX-M type enzymes are the most prevalent extended-spectrum β-lactamases (ESBLs) worldwide including Arab Middle East countries [2, 3] . Among the CTX-M type enzymes, CTX-M-15 has been frequently found in Arab countries over the last decade [3] [4] [5] [6] [7] .
Carbapenems are part of the last line of defense against serious or invasive infections caused by extremely drug-resistant Gram-negative pathogens producing ESBLs [8] [9] .
Prior to the last decade, carbapenem resistance in Enterobacteriaceae was rare. However, Klebsiella pneumonia carbapenemase (KPC), New Delhi metallo-β-lactamase-1 (NDM-1), and recently oxacillinase-48 (OXA-48) have been reported in Enterobacteriaceae isolates [10] .
E. coli species are currently classified into four main phylogenetic groups (A, B1, B2, and D), where A and B1 groups are mainly commensal strains, whereas extraintestinal pathogenic strains are mostly part of B2 and D groups. The clone that belong to the B2 phylogenetic subgroup I, characterized by the multilocus sequence type (MLST) 131 and exhibits a specific O25 type (O25b) [11] .
This new discovered ST131 clone has been recently isolated from a diverse range of infections caused in community and hospitalized patients across the world, and it has been found as ESBL CTX-M-15-producer with a high virulence potential. In addition, ST131 clone has been reported to cause major infection complications from cystitis to lifethreatening sepsis in many countries [4, [12] [13] [14] . Fluoroquinolones and trimethoprim are no longer effective for empiric therapy of E. coli ST131 infections [13] [14] [15] [16] .
This study investigated the occurrence rate of ESBLs, especially metallo-β-lactamases and ST131 clone among E. coli colonized intestines of Jordanian adults.
Population and Methods

Subjects and data collection
A total of 287 feces samples using wet sterile cotton swab immersed in 3 ml 0.85% sterile normal saline tube had been collected from students (one sample from each person) whom age ranged between 18 to 35 years old visiting the University of Jordan Students' Clinic in the period from July 2015 to November 2015. Samples were transported within few hours to the microbiology research lab for culture and further investigation.
The biographic data for each student was obtained and registered on a prepared sheet which included the following: name, gender, age, university number, presence of infection and history of antibiotic treatment during the last 6 months before sampling their stool (Table 2 ).
Culture and identification of E. coli
All collected swabs were cultured directly on MacConkey agar and incubated for 24 hours in 37°C. Five colonies that morphologically represent E. colilike growth were selected from MacConkey culture plates and sub-cultured on MacConkey again to obtain pure E. coli isolates. Lactose-fermenter pure growth on sub-culture plates were confirmed to be E. coli by standard biochemical tests, including citrate utilization, lactose and glucose fermentation on Kligler iron agar tubes, urease and indole production. All confirmed cultures of E. coli isolates were stored in cryotubes that contain Mueller-Hinton agar with 15% glycerol and were stored at -70 ºC. E. coli isolates were later used for antimicrobial susceptibility test, DNA extraction and polymerase chain reaction (PCR) tests.
Antimicrobial susceptibility testing
E. coli isolates were tested using antimicrobial susceptibility disc diffusion method according to the recommendation of the Clinical Laboratory and Standards Institute (CLSI) 2015 [17] . The results were interpreted according to the breakpoints of tested antibiotics as recommended in CLSI 2015 guidelines. E. coli ATCC ® 25922 (ATCC ® is a registered trademark of the American Type Culture Collection) was used as control strain. Minimum inhibitory concentration (MIC) using E-test were used for testing MDR E. coli isolates (Multi-drug resistant; which are resistant to at least 3 classes of antibiotics) including resistant for ciprofloxacin and carbapenemase. The results of susceptibility tests were interpreted according to the guidelines of CLSI.
Extraction of DNA
E. coli isolates stored in cryotubes at -70ºC were thawed at room temperature and cultured onto MacConkey agar. After incubation at 37ºC for 24 hours, a few colonies were picked from the agar, inoculated into Mueller-Hinton broth and incubated at 37ºC for 18 hours (overnight). Then, the bacterial DNA was extracted using the Wizard genomic DNA Purification Kit, Promega, (USA) following manufactures instructions. DNA extracted for each E. coli isolate was quantified to ensure that it is significant for PCR (Concentration > 50 ng/μL), with a purity at A260/A280=1.6-1.8, using Thermo Scientific NanoDrop 1000 Spectrophotometer.
Detection of ESBLs, KPC and ST131
E. coli isolates in cryotubes stored at -70ºC were thawed at room temperature, and cultured onto MacConkey agar. After incubation at 37 ºC overnight few colonies were picked from the agar, and inoculated into 3ml Luria Broth (LB) and incubated for 24 hours at 37ºC. The bacterial plasmid was extracted using the Zyppy™ Plasmid Miniprep Kit, Zymo (USA) according to manufacturer's instructions. Plasmid extraction was done for the identification of plasmid encoded β-lactamases genes (blaCTX-M group I, blaCTX-M- 15 
Agarose gel preparation for gel electrophoresis
Tris Base EDTA (TBE) 1X buffer was prepared; by one part of stock solution 10X with nine parts of distilled water. The agarose gel at concentration of 2% was prepared by dissolving 3.6 gram of agarose powder in 180 ml of 1X buffer and boiling in microwave until agarose completely dissolved, then 8 μl of ethidium bromide (10 mg/ml) was added. The agarose was poured into the electrophoresis tray and left to solidify at room temperature for 20 minutes. After removal of coombs and gates, the gel placed in the electrophoresis tank pre-filled with 1X TBE buffer to be loaded with PCR products.
Statistical analysis
Data were analyzed using Statistical Package for Social Sciences (IBM SPSS) version 21. The level of significance was set at a P value of ≤0.05 to test the hypothesis of no association.
Results
A total of 287 fecal samples were obtained from adult students. Of these samples, 88 were males (30.7%) with average age 21.56 ± 2.26 years and 199 (69.3%) were females with average age 21.8 ± 3.32 years ( Table 2 ). The antimicrobial susceptibility pattern of 287 E. coli isolates is shown in Table 3 . Minimum inhibitory concentrations (MICs) of Multiple Drug Resistant (MDR) E. coli and the MIC ranges for three tested antibiotics (ciprofloxacin, imipenem and meropenem) are given in Table 4 . The distribution of genes for ESBLs, quinolone-resistance, and ST131 clone among 51 MDR representative E. coli isolates are demonstrated in Table 5 .
Sequencing results for ST131 strains
Three randomly picked positive E. coli ST131 isolates were sent for sequencing to Genewiz company, USA. The sequencing results were analyzed by using the website http://www.ecogene.org/gene. Interrogation of the gene database registered sequences with identity homologies were between 98-99% for pabB in three isolates.
Discussion
This study investigated antibiotic resistance profiles for 287 E. coli isolates from fecal samples of adults visiting the students' clinic of the University of Jordan. The study found that 36.6% (105) of these students carried MDR fecal E. coli for at least 3 classes of antibiotics. E. coli ESBL-producers were found to be 45.1% among 105 MDR tested isolates. These results are similar to two recent studies examined fecal samples from hospitalized and out-patient infants admitted to the Pediatric Clinic at JUH during the years 2011 to 2014, and both studies reported rates of 30.6% and 42% MDR E. coli isolates which were ESBL-producers [4, 6] . The emergence of antimicrobial resistance is becoming a serious global health problem worldwide, especially among pathogenic E. coli [1, 23] . Most published data on antimicrobial resistance were obtained from hospitalized or out-patients. Few studies have investigated the occurrence of antimicrobial resistance in a community population. Healthy individuals may carry MDR fecal E. coli, and these individuals can spread their resistant E. coli in their community, and might be a potential source of community infections [24] . A recent study, which was carried at the same period in four medical centers in Jordan and Lebanon over the period between 2011 and 2013, and included samples from patients have UTI and intra-abdominal infection (IAI), has shown that ESBL-producers among E. coli isolates were 43% and 49% in UTI and IAI samples, respectively [26] . A Libyan study investigated 333 Enterobacteriaceae isolates from both patients and healthy controls, and found only 15 (4.5%) isolates were positive for ESBL using the double disc synergy test. The Libyan study also detected that patients were infected with 5.4% of E. coli and 11.4% of K. pneumoniae isolates which were ESBL-producers. Additionally, the study indicated that almost all the ESBL-producing isolates were consistently more resistant to a wide variety of antimicrobial agents than the non-ESBL-producers as it is the case in our study [27] . The low incidence of ESBLproducers in the Libyan study may be due to use a detection test which is not sensitive enough like molecular detection using PCR which was applied in our study and often in other studies. Other recent studies from the Arab Middle East region documented that rates of E. coli ESBL-producers remain higher in clinical samples when compared to healthy persons [5, 28] .
This study showed a relatively high percentage of blaCTX-M group I and blaCTX-M-15 among the MDR E. coli isolates (58.8% and 41.2%, respectively). It has been previously documented that blaC-TX-M-15 group is widely prevalent in Arab Middle East region [3] [4] [5] [6] [7] . Currently, blaCTX-M-15 type is commonly detected in ESBL positive Enterobacteriaceae and others Gram-negative pathogens through the whole world [2, 29] .
This study also demonstrated presence of different β-lactamases other than CTX-M types such as KPC, NDM-1 which had been detected in 11.8%, and VIM in 2% of MDR isolates, while no detection of IMP and OXA-48 was recognized (Table 5) . These results are novel, since no previous study in Jordan has reported on the occurrence of KPC, NDM-1 β-lactamases in E. coli isolates from any source.
This study detected ParC and gyrA quinoloneresistance genes among all 51 MDR E. coli isolates. This high percentage may indicate extensive consumption of fluoroquinolones in Jordan according to our available information. Another suspected factor which may contribute to high fluoquinolone-resistance is the dissemination of ST131 E. coli clone [4, 30] . The present study shows that E. coli ST131 clone carrying the pabB gene and ciprofloxacin-resistant was accounted for 49% of MDR E. coli isolates. This result is relatively high when compared to a recent study investigated fecal E. coli isolates from Jordanian infants admitted to the JUH, and found only 9 isolates (7.2%) to be positive for ST131 clone [4] . A study in US found that ST131 accounted for 46% of ESBL-positive E. coli isolates [30] . Other studies from developed countries reported on the emergence of E. coli ST131 types in geriatric patients and among hospitalized patients colonized intestinally with fluoroquinolone-resistant E. coli. [30] [31] [32] . In addition, a recent paper from Japan, found Type 131 C1-M27 subclone, among ESBL-Producing E. coli in wastewater [33] .
This study suggests that continuous increasing incidence of E. coli producing ESBL and fluoquinoloneresistance in intestinal tract of population would make the treatment of infections caused by E. coli, especially community UTIs more difficult and challenging.
